JR Biomedical Ltd has an active R&D program for the development of new lateral flow rapid diagnostics for both clinical and self test use.
- A pipeline of new SELFCheck products are planned and will be registered and released for sale during 2018-2022, doubling the number of products that were available in 2018 when JR Biomedical Ltd acquired 1st Health Products Ltd
- A new point of care test for the early diagnosis of sepsis is under development with a UK university and will be launched for clinical use in Q1, 2022
- Collaboration with UK universities for the development of a homogeneous immunoassay system for use in hospital laboratories
We are keen to collaborate with universities and pharmaceutical companies for the development of new in-vitro diagnostics.
Further information on social media.